A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

Phase 3 Unknown 8 enrolled Kobe University Boehringer Ingelheim · collab

NaSingle-groupOpen-labelTreatment

Summary

A multicenter, open-label, single-arm study with regard to the efficacy and safety of empagliflozin in patients with refractory diabetes mellitus with insulin resistance

Timeline

Start: 2019-09-01
Primary completion: 2021-07-31
Completion: 2021-10-30

Publications

Hirota Y, Kakei Y, Imai J, Katagiri H, Ebihara K, Wada J, Suzuki J, Urakami T, Omori T, Ogawa W. A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01). Diabetes Ther. 2024 Feb;15(2):533-545. doi: 10.1007/s13300-023-01526-x. Epub 2024 Jan 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Empagliflozin	Small molecule	10 mg	Oral
Subject	Empagliflozin	Small molecule	25 mg	Oral

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

Summary

Timeline

Publications

Drugs

Indications